Uric Acid and Pentraxin-3 Levels Are Independently Associated with Coronary Artery Disease Risk in Patients with Stage 2 and 3 Kidney Disease
- 10 March 2011
- journal article
- Published by S. Karger AG in American Journal of Nephrology
- Vol. 33 (4), 325-331
- https://doi.org/10.1159/000324916
Abstract
Background and Objectives: Cardiovascular disease is prevalent in chronic kidney disease (CKD). Uric acid is increased in subjects with CKD and has been linked with cardiovascular mortality in this population. However, no study has evaluated the relationship of uric acid with angiographically proven coronary artery disease (CAD) in this population. We therefore investigated the link between serum uric acid (SUA) levels and (i) extent of CAD assessed by the Gensini score and (ii) inflammatory parameters, including C-reactive protein (CRP) and pentraxin-3, in patients with mild-to-moderate CKD. Material and Methods: In an unselected population of 130 patients with estimated glomerular filtration rate (eGFR) between 90 and 30 ml/min/1.73 m2, we measured SUA, serum pentraxin-3, CRP, urinary protein-to-creatinine ratio, lipid parameters and the severity of CAD as assessed by coronary angiography and quantified by the Gensini lesion severity score. Results: The mean serum values for SUA, pentraxin-3 and CRP in the entire study population were 5.5 ± 1.5 mg/dl, 6.4 ± 3.4 ng/ml and 3.5 ± 2.6 mg/dl, respectively. The Gensini scores significantly correlated in univariate analysis with gender (R = –0.379, p = 0.02), uric acid (R = 0.42, p = 0.001), pentraxin-3 (R = 0.54, p = 0.001), CRP (R = 0.29, p = 0.006) levels, eGFR (R = –0.33, p = 0.02), proteinuria (R = 0.21, p = 0.01), and presence of hypertension (R = 0.37, p = 0.001), but not with smoking status, diabetes mellitus, and lipid parameters. After adjustments for traditional cardiovascular risk factors, only uric acid (R = 0.21, p = 0.02) and pentraxin-3 (R = 0.28, p = 0.01) remained significant predictors of the Gensini score. Conclusions: SUA and pentraxin-3 levels are independent determinants of severity of CAD in patients with mild-to-moderate CKD. We recommend a clinical trial to determine whether lowering uric acid could prevent progression of CAD in patients with CKD.Keywords
This publication has 52 references indexed in Scilit:
- Uric Acid-Lowering Treatment With Benzbromarone in Patients With Heart FailureCirculation: Heart Failure, 2010
- Uric Acid and Long-term Outcomes in CKDAmerican Journal of Kidney Diseases, 2009
- Uric Acid Is a Danger Signal Activating NALP3 Inflammasome in Lung Injury Inflammation and FibrosisAmerican Journal of Respiratory and Critical Care Medicine, 2009
- Small arterial elasticity predicts the extent of coronary artery disease: Relationship with serum uric acidAtherosclerosis, 2009
- Uric acid: bystander or culprit in hypertension and progressive renal disease?Journal of Hypertension, 2008
- Low Serum Uric Acid Level Is a Risk Factor for Death in Incident Hemodialysis PatientsAmerican Journal of Nephrology, 2008
- J-Shaped Mortality Relationship for Uric Acid in CKDAmerican Journal of Kidney Diseases, 2006
- Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third national health and nutrition examination surveyAmerican Journal of Kidney Diseases, 2003
- Uric Acid, Hominoid Evolution, and the Pathogenesis of Salt-SensitivityHypertension, 2002
- Production of the Long Pentraxin PTX3 in Advanced Atherosclerotic PlaquesArteriosclerosis, Thrombosis, and Vascular Biology, 2002